May 23, 2017

May 23, 2017

Subscribe to Latest Legal News and Analysis

May 22, 2017

Subscribe to Latest Legal News and Analysis

Amgen Sues Coherus Under BPCIA After Completing Patent Dance

On May 10, 2017, Amgen filed a complaint in the District of Delaware asserting that, under section 35 U.S.C. § 271(e)(2)(C)(i) of the Biologics Price Competition and Innovation Act (“BPCIA”), Coherus infringed Amgen’s U.S. Patent No. 8,273,707 (the “’707 patent”) by filing an abbreviated Biologic License Application (“aBLA”) for a biosimilar version of Amgen’s Neulasta (pegfilgrastim) product. Amgen asserted that the biosimilar manufacturing process disclosed in the Coherus aBLA will infringe the ’707 patent’s claimed protein purification process.

In contrast with some other pending BPCIA infringement suits, the parties here apparently followed all steps of the BPCIA “patent dance” information exchange procedure codified at 42 U.S.C. § 262(l). Specifically, Coherus allegedly submitted its aBLA in August 2016 and, around October 6, 2016, received notification from FDA that the aBLA was accepted. In accordance with § 262(l)(2), the parties began the patent dance on October 11, 2016 when Coherus notified Amgen of the aBLA acceptance by FDA. Amgen and Coherus then followed the patent dance steps by exchanging: a copy of the aBLA (§ 262(l)(2)), Amgen’s list of patents that it may reasonably assert in an infringement action (§ 262(l)(3)(A)), Coherus’ response to Amgen’s list and its own proposed list of patents that may reasonably asserted (§ 262(l)(3)(B)), and Amgen’s detailed statement in response to Coherus’ list (§ 262(l)(3)(C)). At the conclusion of the dance, the parties agreed that the ’707 patent would be included in the “first wave” BPCIA infringement action (§ 262(l)(4)(A)), and Amgen filed the instant action no more than 30 days later, pursuant to § 262(l)(6).

The parties’ decision to follow the entire patent dance contrasts with some other BPCIA infringement actions in which the parties engaged in none or only some of the statutory information exchange. For example, as we previously reported in Amgen v. Sandoz, recently argued before the Supreme Court, the aBLA applicant deliberately refused to engage in even the initial steps of dance. While the Supreme Court’s eagerly anticipated ruling on the issue is not expected until June, and current Federal Circuit authority on the issue renders the dance optional, Coherus and Amgen apparently chose to engage in the entire BPCIA information exchange process.

Finally, we note that in March 2017, Amgen sued Coherus in California State Superior Court alleging a “massive conspiracy” by Amgen’s former employees in founding Coherus and inducing former Amgen employees to misappropriate Amgen’s trade secrets related to the manufacture and sale of pegfilgrastim. While both actions involve the same Coherus pegfilgrastim biosimilar product, they appear to raise distinct causes of action.

©1994-2017 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. All Rights Reserved.

TRENDING LEGAL ANALYSIS


About this Author

Thomas H. Wintner, Mintz Levin, Complex Litigation Lawyer,
Member

Tom focuses on complex litigation, at both the trial and appellate levels, for clients in a wide range of industries. He has successfully tried cases in both state and federal courts, and has guided others through mediation and arbitration. In his appellate practice, Tom has secured victories for clients in the First, Fourth, Ninth, and Federal Circuit Courts of Appeal as well as the Massachusetts Appeals Court.

In matters involving intellectual property, Tom draws on his prior experience as a research chemist. He represents life sciences...

617.348.1625
Joseph D. Rutkowski, Mintz Levin, Civil Litigation Matters Lawyer, Intellectual Property Litigation Matters
Associate

Joseph’s practice focuses on a variety of civil litigation matters, including patent litigation, trade secret disputes, and complex commercial litigation. Joseph’s primary focus is intellectual property litigation, and he is experienced in many aspects, including expert discovery and pretrial motion practice.

In addition, Joseph gained valuable experience representing a homeless shelter, pro bono, as lead attorney in over a dozen housing court matters, including summary process jury trial and mediations, and he supervised junior associates on related matters.

Prior to joining Mintz Levin, Joseph was an associate in the Boston litigation practice of another international law firm. During law school, Joseph was an editor on the Boston University Law Review.

Before law school, Joseph was a business and systems integration consultant, and he worked with Fortune 500 clients to implement enterprise-wide IT systems across US markets. 

617.348.1873